This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Under-Promise and Over-Deliver

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- The first rule of growth stocks is under-promise and over-deliver, Jim Cramer told his "Mad Money" TV show viewers Wednesday as he opined on the backlash seen in Apple (AAPL) stock after what was widely perceived as a ho-hum iPhone announcement Tuesday.

Cramer said that Apple, a stock he owns for his charitable trust, Action Alerts PLUS , just didn't get the under-promise message when investors had similar lackluster reactions to the company's products this time last year. At the time, CEO Tim Cook said that 2013 would be a big year for Apple. To date, the company's one announcement touted colorful iPhones with better security.

Growth stocks often learn the under-promise, over-deliver, or UPOD, message the hard way, said Cramer, as Chipotle Mexican Grill (CMG) and Starbucks (SBUX) have in the past. But lately both of those companies have managed expectations and continue to wow investors every quarter.

"Never promise what can't be delivered," said Cramer. Shareholders have the right not to be disappointed.

What could Apple have done in 2013 to wow investors? Cramer said why not buy Twitter, or Netflix (NFLX), or both? Why not do something to reinvigorate growth more than simple buybacks and dividends? Wall Street needs, and even craves, growth, Cramer concluded, which is why so many analysts jumped on the downgrade bandwagon today.

Executive Decision: Francois Nader

In his first "Executive Decision" segment, Cramer spoke with Dr. Francois Nader, president and CEO of orphan drug maker NPS Pharmaceuticals (NPSP), a stock that's up 238% since Cramer first highlighted the company a year ago.

Nader said that he's very pleased with his company's prospects. NPS plans on filing for its next drug approval by the end of this year and is proceeding with global expansion plans early next year. After that, Nader said his company's pipeline will continue to expand as its drug, Gattex, expands into new indications.

Nader said the market opportunities are huge for NPS and extend far beyond the few hundred patients the company currently services. Not all patients will have to pay the $295,000 annual price tag for Gattex, but there are far more patients that could benefit from the treatment.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,161.12 +29.15 0.17%
S&P 500 2,004.93 +5.95 0.30%
NASDAQ 4,569.3640 +16.6050 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs